Health Economics, Pharmaco-economics and Health Technology Assessment Reports

 

2013.


Valentin Brodszky dr. Ph.D., Márta Péntek  dr. Ph.D., habil., Petra Baji  Ph.D., Prof. László Gulácsi :
Az Enzalutamide (MD3100) szerepe a prosztatarák terápiájában; szisztematikus irodalmi áttekintés és egészség-gazdaságtani értékelés
Technology Assessment Report, October, 2013

Prof. László  Gulácsi  dr. Ph.D., Márta Péntek  dr. Ph.D., Petra Baji Ph.D. Orsolya Balogh , Valentin Brodszky  dr. Ph.D:
Az infliximab (Celltrion-EGIS) kezelés felnőttkori colitis ulcerosában; irodalmi áttekintés és egészség-gazdaságtani elemzés
Technology Assessment Report, September, 2013

Valentin Brodszky M.D. Ph.D., Petra Baji Ph.D. Orsolya Balogh, Prof. László Gulácsi M.D. Ph.D., Márta Péntek MD. Ph.D.:
Systematic review and analysis of evidences on effectiveness and cost-effectiveness of infliximab and comparator biologicals for Ankylosing Spondylitis
Technology Assessment Report, March, 2013

Valentin Brodszky M.D. Ph.D., Márta Péntek MD. Ph.D., Petra Baji Ph.D., Orsolya Balogh, Prof. László Gulácsi M.D. Ph.D.: Systematic review and analysis of evidences on effectiveness and cost-effectiveness of infliximab and comparator biologicals for Psoriasis
Technology Assessment Report, February, 2013

2012.


Prof. László Gulácsi  dr. Ph.D., Márta Péntek dr. Ph.D., Petra Baji,  Orsolya Balogh, Noémi Vártokné Hevér, Valentin Brodszky dr. Ph.D: Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of infliximab and comparator biologicals for adult Crohn’s Disease
Technology Assessment Report, May, 2012

Márta Péntek MD. Ph.D., Valentin Brodszky M.D. Ph.D., Petra Baji, Noémi Hevér, Orsolya Balogh, Prof. László Gulácsi M.D. Ph.D.: Systematic review and analysis of evidences on effectiveness and cost-effectiveness of infliximab and comparator biologicals for Psoriatic Arthritis
Technology Assessment Report, May, 2012

Márta Péntek MD. Ph.D., Valentin Brodszky M.D. Ph.D., Petra Baji, Noémi Hevér, Orsolya Balogh, Prof. László Gulácsi M.D. Ph.D.: Systematic review and analysis of evidences on effectiveness and cost-effectiveness of infliximab and comparator biologicals for Rheumatoid Arthritis
Technology Assessment Report, May, 2012

 

2011.


Valentin Brodszky  dr. PhD, László Gulácsi  dr. Ph.D. habil, Márta Péntek dr. PhD, Petra Baji:  Az Alprestil (alprostadil) szerepe a perifériás artériás obliteratív érbetegségek terápiájában: irodalmi áttekintés és egészség-gazdaságtani értékelés
Technology Assessment Report, October, 2011

Valentin Brodszky  dr. PhD, László Gulácsi  dr. Ph.D. habil, Márta Péntek dr.PhD, Petra Baji :
A capsaicin 8%-os (Qutenza) tapasz szerepe a nem diabéteszes, perifériás neuropátiás fájdalom terápiájában: irodalmi áttekintés és egészség-gazdaságtani értékelés
Technology Assessment Report, October, 2011

2010.


Márta Péntek  dr., Ph.D., Valentin Brodszky  dr. Ph.D., Petra Baji , László Gulácsi  dr., Ph.D., habil: Technológiaelemzési Jelentés Az Orencia® (abatacept) szerepe a Polyarticularis Juvenilis Idiopathias Arthritis terápiájában: szakirodalmi áttekintés és egészséggazdaságtani elemzés
Technology Assessment Report, June, 2010

 

2007.


 

Valentin Brodszky MD., Márta Péntek MD., László Gulácsi MD. Ph.D., habil.: Infliximab in patients with arthritis psoriatica: systematic review of the clinical and economic literature
Technology Assessment Report, December, 2007

 

Valentin Brodszky MD., Márta Péntek MD., Krisztián Kárpáti, László Gulácsi MD. Ph.D., habil.: Parenteral methotrexate in patients with rheumatoid arthritis: systematic review, crossectional study and economic evaluation
Technology Assessment Report, November, 2007

 

Valentin Brodszky MD., Márta Péntek MD., István Májer, Krisztián Kárpáti, László Gulácsi MD. Ph.D., habil.:Economic evaluation of the first TNF-alpha inhibitor therapy in patients with rheumatoid arthritis
Technology Assessment Report – September, 2007

 

Valentin Brodszky MD., Márta Péntek MD., István Májer, Krisztián Kárpáti, László Gulácsi MD. Ph.D., habil.: Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation
Technology Assessment Report, – June, 2007

 

2006.


 

Valentin Brodszky MD., Márta Péntek MD., István Májer, Krisztián Kárpáti, László Gulácsi MD. Ph.D., habil.:Etanercept in patients with Juvenile Idiopathic Arthritis: systematic review and economic evaluation
Technology Assessment Report, November, 2006

 

Valentin Brodszky MD., Márta Péntek MD., István Májer, Krisztián Kárpáti, László Gulácsi MD. Ph.D., habil.:
Rituximab in patients with rheumatoid arthritis: systematic review and economic evaluation
Technology Assessment Report, October – 2006

 

István Májer, Márta Péntek MD., Valentin Brodszky MD., László Gulácsi MD. Ph.D.: Health economics modelling: costs, effectiveness and cost-effectiveness of biological agents in rheumatoid arthritis with particular emphasis on infliximab (REMICADEâ) therapy
Technology Assessment Report, June, 2006

 

2005.


Ágnes Brandtmüller, Krisztián Kárpáti, István Májer, Valentin Brodszky MD., László Gulácsi MD. Ph.D.: Clical effectiveness of carvedilol incomparison to -blockers, systematic review of the clinical and economic literature
Health economics and Pharmaco-economics research, December, 2005

 

Krisztián Kárpáti, Valentin Brodszky MD., László Gulácsi MD. Ph.D.: Methodological issues of cost-effectiveness analysis. Phase 4.:Priority setting and cost-effectiveness financing thresholds; systematic literature review and evaluation of the adaptability of results from other jurisdictions
Technology Assessment Report, December, 2005

 

Valentin Brodszky, MD. László Gulácsi MD., Ph.D.: Biologicals in patients with psoriasis, infliximab (REMICADEâ) therapy
Technology Assessment Report, November, 2005

 

Valentin Brodszky MD., Krisztián Kárpáti, László Gulácsi MD. Ph.D.: Clinical effectiveness of indapamide; systematic review of the clinical and economic literature
Technology Assessment Report, November, 2005

 

Valentin Brodszky MD., Márta Péntek MD., Mariann Nagy MD., László Gulácsi MD. Ph.D.: Biologicals in patients with arthritis psoriatica, infliximab (REMICADEâ) therapy
Technology Assessment Report, September,  2005

 

Mariann Nagy MD., Márta Péntek MD., Valentin Brodszky MD., László Gulácsi MD. Ph.D.: Biologicals in patients with spondylitis ankylopoetica; the (REMICADEâ) therapy
Technology Assessment Report, September, 2005

 

László Gulácsi MD. ph.D., Krisztián Kárpáti, Prof. Zoltán Vincze., István Májer, Anikó Lepp-Gazdag: Methodological issues of cost-effectiveness analysis. Phase 3.: Health economics in drug coverage policy and financing
Health economics and Pharmaco-economics research, August, 2005

 

László Gulácsi MD., István Májer, Krisztián Kárpáti, Patricia Zámbó:Methodological issues of cost-effectiveness analysis . Phase 2.: Costing in health care; costing guideline for Hungary
Technology Assessment Report, June , 2005

 

László Gulácsi MD. Ph.D., István Májer, Krisztián Kárpáti, Anikó Lepp-Gazdag, Prof. Marc Koopmanshap., Prof. Frans Rutten: Paclitaxel-Eluting Coronary Stent System in cardiovascular treatment; systematic review of the clinical and economic literature
Health economics and Pharmaco-economics research, June, 2005

 

László Gulácsi MD. Ph.D., Imre Boncz MD., Ágnes Brandtmüller, Krisztián Kárpáti, Anikó Lepp-Gazdag, István Májer, Prof. György Jenei: Methodological issues of cost-effectiveness analysis – Phase 1: Transferability and adaptability of health economics and technology assessment results
Health economics and Pharmaco-economics research, April, 2005

 

László Gulácsi MD., PhD., Márta Péntek MD., István Májer, Valentin Brodszky MD., Anikó Lepp-Gazdag:Infliximab (REMICADEâ) in patients with rheumatoid arthritis: systematic review of the clinical and economic literature. Results from a 6 centrer, 255 patients cross-sectional study, 2004.
Technology Assessment Report, March, 2005

 

László Gulácsi MD., Ph.D., Anikó Lepp-Gazdag, István Májer, Márta Péntek MD.: Glargin insulin (Lantus) in patients with diabetes; systematic review of the clinical and economic literature. Results from an 18 centers 550 patients cross sectional questionnaire survey; treatment pattern, costs and quality of life
Technology Assessment Report, February, 2005